| Platinum-Sensitive Malignant Female Reproductive System Neoplasm studied in …STUDIED_INderived26 of 26show fewer |
|---|
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225270Phase 3 · recruiting Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07564141Phase 3 · recruiting Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776171Phase 2 · not yet recruiting Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04550494Phase 2 · active not recruiting Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05579366Phase 1/Phase 2 · recruiting Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627443Phase 1 · active not recruiting Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024784Phase 2 · recruiting A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07454018Phase 2 · not yet recruiting Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04457089early Phase 1 · completed Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07295132Phase 2 · not yet recruiting RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06686030Phase 2 · recruiting Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04713514Phase 2 · active not recruiting OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691376Phase 1 · terminated Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Fallopian Tube Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05002868Phase 1 · completed Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04907968Phase 1 · terminated Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01847274Phase 3 · completed A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978222Phase 2 · terminated Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05069818unknown Variance of HRD From Paired Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01837251Phase 3 · completed Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01611558Phase 2 · completed Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02035345Phase 4 · terminated Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment · condition mapped ALIAS · 26 trials mapped (15 active) | — | — | Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |